Abstract
We investigated the efficacy of an eutectic mixture of local anesthetics (EMLA®) in reducing the pain of a botulinum toxin injection into eyelids. 17 patients with facial dyskinesia (9 blepharospasm and 8 hemifacial spasm) who had been treated regularly with botulinum toxin injections received EMLA cream and placebo. The pain was assessed by the ophthalmologist and the patient. Injection with EMLA cream showed lower pain scores (mean 1.82 ± 2.13, median 1) than injection with placebo (8.76 ± 2.17; p = 0.0001). Percutaneous anesthesia induced by EMLA cream is an effective and safe method which improves the comfort in patients who need repeated botulinum toxin injections for their facial dyskinesia.
References
1.
Osako M, Keltner JL: Botulinum A toxin (Oculinum) in ophthalmology. Surv Ophthalmol 1991;36:28–46.
2.
Özkan SB, Can D, Söylev MF, Arsan AK, Duman S: Chemodenervation in treatment of upper eyelid retraction. Ophthalmologica 1997;211:387–390.
3.
Dutton JJ, Buckley EG: Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988;95:1529–1534.
4.
Ainswoth JR, Kraft SP: Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm. Ophthalmology 1995;102:2036–2040.
5.
Adler CH, Zimmerman RA, Savino PJ, Bernard B, Bosley TM, Sergott FC: Hemifacial spasm evaluation by magnetic resonance imaging and magnetic resonance tomographic angiography. Ann Neurol 1992;32:502–506.
6.
Gonnering RS: Treatment of hemifacial spasm with botulinum A toxin results and rationale. Ophthalmic Plast Reconstr Surg 1986;2:143–146.
7.
Dutton JJ: Botulinum-A toxin in the treatment of craniocervical muscle spasms: Short- and long-term, local and systemic effects. Surv Ophthalmol 1996;41:51–65.
8.
Kalra HK, Magoon EH: Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm. Ophthalmic Surg 1990;21:335–338.
9.
Perman KI, Baylis HI, Rosenbaum AL, Kirschen DG: The use of botulinum toxin in the medical management of benign essential blepharospasm. Ophthalmology 1986;83:1–3.
10.
Engstrom PF, Arnoult JB, Mazow ML, Prager TC, Wilkins RB, Byrd WA, Hofmann RJ: Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology 1987;94:971–975.
11.
Kristan RW, Stasior OG: Treatment of blepharospasm with high dose brow injection of botulinum toxin. Ophthalmic Plast Reconstr Surg 1987;3:25–27.
12.
Grandas F, Elston J, Quinn N, Marsden CD: Blepharospasm: A review of 264 patients. J Neurol Neurosurg Psychiatr 1988;51:767–772.
13.
Sunderraj P, Kirby J, Jojce PW, Watson A: A double masked evaluation of lignocoine-prilocaine cream (EMLA) used to alleviate the pain of retrobulbar injection. Br J Ophthalmol 1991;75:130–132.
14.
Hallen B, Carlsson P, Uppfeldt A: Clinical study of a lignocaine-prilocaine cream to relieve the pain of venepuncture. Br J Anaesth 1985;57:326–328.
15.
Maunuksela EL, Korpela R: Double-blind evaluation of a lignocaine-prilocaine cream in children. Br J Anaesth 1986;58:1242–1245.
16.
Smith M, Gray BM, Ingram S, Jewkes DA: Double-blind comparison of topical lignocaine-prilocaine cream (EMLA) and lignocaine infiltration for arterial cannulation in adults. Br J Anaesth 1990;65:240–242.
17.
Gotsis SS, Volonaki OM, Theodossiadis GP: Percutaneous anaesthesia with a lignocaine-prilocaine cream (EMLA) for eyelid skin surgery. Br J Ophthalmol 1994;78:209–210.
18.
Price J, Farish S, Taylor H, O’Day J: Blepharospasm and hemifacial spasm. Randomised trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology 1997;104:865–868.
19.
Frueh BR, Felt DP, Wojno TH, Musch DC: Treatment of blepharospasm with botulinum toxin: A preliminary report. Arch Ophthalmol 1984;102:1464–1468.
20.
Kapelushnik J, Koren G, Solh H, Greenberg M, Deveber L: Evaluating the efficacy of EMLA in alleviating pain with lumbar puncture; comparison of open and double-blinded protocols in children. Pain 1990;42:31–34.
21.
Hopkins CS, Buckley CJ, Bush GH: Pain-free injection in infants. Anaesthesia 1988;43:198–201.
22.
Enk AH: EMLA cream induced eye injury. Arch Dermatol 1999;135:855–856.
23.
Evers H, Von Dardel O, Juhlin L, Ohlsen L, Vinnars E: Dermal effects of compositions based on the eutectic mixture of lignocaine and prilocaine (EMLA). Br J Anaesth 1985;51:991–1005.
24.
Bjerring P, Andersen PH, Arendt-Nielsen L: Vascular response of human skin after analgesia with EMLA cream. Br J Anaesth 1989;63:655–660.
25.
Browne J, Raza A, Awad I, Tan B, McAdoo J, Shorten G: The effects of EMLA and a topical formulation of 4% amethocaine (Ametop®) on pain associated with retrobulbar injection. Anaesthesia 1999;54:596–598.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.